Abstract 40MO
Background
To characterize the mutational landscape of mucinous epithelial ovarian cancer (MOC).
Methods
Data were extracted from the American Association for Cancer Research’s (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) database version 12.1 via cBioPortal (http://genie.cbioportal.org). This publicly available, multi-institutional database provides next generation sequencing genomic profiles of tumors. We queried this database for MOC samples and descriptively report mutation frequencies of genes for which targeted therapies are either approved or in clinical trials for other cancer types. We include the following genes in our analysis: ERBB2 (HER2) amplifications, homologous recombination (HR) and mismatch repair (MMR) genes, BRAF, KRAS, NRAS, RNF43, ARID1A, PIK3CA, ERBB3, and PTEN mutations.
Results
Among 145 MOC samples, the most common somatic mutations were KRAS (98/145, 67.6%), ERBB2 (HER2) amplification (13/90, 14.4%), ARID1A (16/116, 13.8%), CDKN2A (17/141, 12.1%), PIK3CA (13/145, 9.0%), ERBB3 (10/120, 8.3%), RNF43 (7/102, 6.9%), BRAF (4/145, 2.8%), PTEN (4/145, 2.8%), and NRAS (2/145, 1.4%). Mutations in HR and MMR genes were relatively rare, with the most common HR mutations in BRIP 1 (5/114, 4.4%) and BRCA2 (5/122, 4.1%); and the most common MMR mutations in MLH3 (1/44, 2.3%) and MSH3 (1/48, 2.1%). Table: 40MO
Mutation frequencies of homologous recombination (HR) and mismatch repair (MMR) genes, as well as the TP53 gene in tumor samples from mucinous ovarian cancer
No. of samples with ≥1 mutation | No. of samples profiled for mutation | Mutation frequency | |
BRCA1 | 5 | 122 | 1.6% |
BRCA2 | 5 | 122 | 4.1% |
BRIP1 | 5 | 114 | 4.4% |
CHEK2 | 1 | 116 | 0.9% |
PALB2 | 2 | 116 | 1.7% |
MSH3 | 1 | 48 | 2.1% |
MSH6 | 1 | 120 | 0.8% |
MLH3 | 1 | 44 | 2.3% |
PMS2 | 1 | 113 | 0.9% |
TP53 | 91 | 145 | 62.8% |
Conclusions
Advanced stage MOC carries a poor prognosis, with only platinum/taxane, anti-VEGF agents, and 5-fluouracil currently available as current standard of care therapies. Here, we demonstrate high mutation rates in targetable genes among MOC samples. Most commonly, these mutations were identified among KRAS/NRAS (targetable with MEK inhibitors), ERBB2 (HER2) (targetable with anti-HER2 agents), ARID1A (targetable with epigenetic modifiers and ATR inhibitors), and PI3CA (targetable with PI3-kinase and AKT inhibitors). Given the frequency of each mutation, genetically targeted clinical trials evaluating the clinical efficacy of their respective agents are warranted.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
36MO - Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC): 5-year (y) progression-free survival (PFS) by molecular subgroup in the PAOLA-1/ENGOT-ov25 trial
Presenter: Antonio Jose Gonzalez Martin
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
37MO - Niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a post hoc analysis on efficacy by surgical timing and residual disease status in the phase III PRIME trial
Presenter: Lingya Pan
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
Invited Discussant of abstracts 36MO and 37MO
Presenter: Rebecca Kristeleit
Session: Mini Oral session
Resources:
Slides
Webcast
22MO - Homologous Recombination Gene Mutations in Uterine Serous Cancer: A Phenotype of the Hereditary Breast and Ovarian Cancer Syndrome?
Presenter: Muhammad Danyal Ahsan
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
38MO - Validation study of the shallowHRDv2 assay for Homologous Recombination Deficiency (HRD) detection in high-grade ovarian carcinomas (HGOC) in the first-line setting, from the phase III PAOLA-1/ENGOT-ov25 trial
Presenter: Céline Callens
Session: Mini Oral session
Resources:
Abstract
39MO - Clinical evaluation of a low-coverage whole-genome test for homologous recombination deficiency detection in ovarian cancer
Presenter: Romain Boidot
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
1MO - Identification of RAD51 foci in cancer-associated circulating cells and their association with treatment outcomes, in patients with high-grade serous ovarian cancer (HGSOC)
Presenter: Marcia Hall
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
Invited Discussant of abstracts 22MO, 38MO, 39MO and 1MO
Presenter: Iain McNeish
Session: Mini Oral session
Resources:
Slides
Webcast
74MO - Clinical outcomes for pelvic node-positive vulvar carcinoma in the PET and IMRT era: reassessing the Stage IVb designation
Presenter: Sean Koerner
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
Invited Discussant of abstracts 40MO and 74MO
Presenter: Robert Coleman
Session: Mini Oral session
Resources:
Slides
Webcast